NCT06486779
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study No drug interventions Not Available Not Available not_yet_recruiting NCT04130997
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis treatment 3 active_not_recruiting NCT03277261
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) treatment 3 completed NCT04878211
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab treatment 4 terminated NCT04667949
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients treatment 4 active_not_recruiting NCT03277248
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) treatment 3 completed NCT03745144
Effects of Cladribine Tablets on the PK of Microgynon® other 1 completed NCT02921035
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS) Not Available Not Available completed NCT04086225
Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon® other 1 recruiting NCT01585766
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis treatment 1 completed NCT03650114
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS treatment 3 active_not_recruiting NCT04667117
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab treatment 4 completed NCT05232825
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis treatment 3 active_not_recruiting NCT04586010
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) treatment 3 active_not_recruiting NCT05119569
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) treatment 2 active_not_recruiting NCT05147220
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) treatment 3 recruiting NCT05156281
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) treatment 3 recruiting NCT05199571
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China treatment 4 active_not_recruiting NCT05877963
Study to Evaluate Efficacy of a Modified Regimen of Ublituximab treatment 3 recruiting NCT06143514
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk No drug interventions Not Available Not Available recruiting NCT06396039
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis treatment 4 recruiting NCT06433752
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) No drug interventions Not Available Not Available recruiting NCT06564311
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) treatment 2 recruiting NCT06617793
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis No drug interventions treatment 1 / 2 not_yet_recruiting NCT04626921
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis treatment 2 / 3 completed NCT01939002
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) treatment 3 completed NCT01034579
The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial No drug interventions Not Available 4 completed NCT05090033
Characterizing the Use of Ofatumumab in a Real World Setting No drug interventions Not Available Not Available active_not_recruiting NCT00472797
Rebif New Formulation (RNF) Quality of Life (QOL) Study supportive_care 3 completed NCT06104683
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis treatment 2 withdrawn NCT04338061
Study of Evobrutinib in Participants With RMS (evolutionRMS 2) treatment 3 terminated NCT04047628
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) treatment 3 recruiting NCT04410978
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) treatment 3 active_not_recruiting NCT04079088
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) treatment 2 withdrawn NCT00619307
Transition to Rebif New Formulation supportive_care 3 completed NCT06395909
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis No drug interventions Not Available Not Available completed NCT02241785
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies treatment 4 terminated NCT00988052
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course treatment 3 terminated NCT06526000
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies No drug interventions Not Available Not Available completed NCT01070836
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab Not Available Not Available completed NCT04928313
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran Not Available Not Available completed NCT02792218
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis treatment 3 completed NCT01601119
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients Not Available Not Available completed NCT01006941
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study No drug interventions treatment 2 completed NCT01404117
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability treatment 2 withdrawn NCT02047734
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis treatment 3 completed NCT04486716
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis treatment 3 active_not_recruiting NCT04847596
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab No drug interventions Not Available Not Available completed NCT03257358
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod basic_science 4 completed NCT05809986
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study No drug interventions Not Available Not Available recruiting NCT04121065
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) No drug interventions Not Available Not Available recruiting NCT04510220
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis treatment 3 recruiting NCT04634994
Novel Assessment of Synaptic Density in Progressive MS No drug interventions diagnostic 0 unknown_status NCT03996291
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis treatment 2 active_not_recruiting NCT00853762
Atacicept in Multiple Sclerosis Extension Study, Phase II treatment 2 terminated NCT04353492
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab treatment 3 active_not_recruiting NCT05266469
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf No drug interventions Not Available Not Available active_not_recruiting NCT03249714
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab treatment 2 completed NCT03623243
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients treatment 3 completed NCT04121403
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) treatment 3 recruiting NCT00642902
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) treatment 2 terminated NCT01412333
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis treatment 3 completed NCT06372145
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. treatment 3 recruiting NCT01199861
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) treatment 3 completed NCT01628393
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients treatment 2 / 3 completed NCT05776888
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years No drug interventions Not Available Not Available recruiting NCT05077956
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis No drug interventions Not Available Not Available withdrawn NCT02688985
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) treatment 3 completed NCT00906399
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis treatment 3 completed NCT06529406
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod treatment 1 / 2 not_yet_recruiting NCT03856619
To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis treatment 4 completed NCT01047319
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis treatment 3 terminated NCT01332019
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a treatment 3 completed NCT04387734
Effects of Ocrevus in Relapsing Multiple Sclerosis treatment 4 active_not_recruiting NCT01247324
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis treatment 3 completed NCT03889639
Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis treatment 2 completed NCT04338022
Study of Evobrutinib in Participants With RMS (evolutionRMS 1) treatment 3 terminated NCT00726648
CDP323 Biomarker Study basic_science 1 / 2 completed NCT05496894
A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis treatment 2 withdrawn NCT04410991
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) treatment 3 active_not_recruiting NCT01601080
An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device No drug interventions Not Available Not Available completed NCT02142192
Natalizumab Subcutaneous Immunogenicity and Safety Study treatment 2 terminated NCT02254304
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ treatment 4 completed NCT05344469
A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT03183869
Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients treatment 2 terminated NCT02234869
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy treatment 4 withdrawn NCT01127750
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients treatment 3 completed NCT04466150
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset basic_science 4 active_not_recruiting NCT04586023
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) treatment 3 active_not_recruiting NCT04964791
RMS Study of BTK Inhibitor SAR442168 Not Available Not Available recruiting NCT02307838
Long-term Follow-up of Fingolimod Phase II Study Patients No drug interventions other 4 completed NCT05798520
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) No drug interventions treatment 2 recruiting NCT05083923
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) treatment 3 completed NCT02428218
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) treatment 3 withdrawn NCT01216072
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis treatment 4 completed NCT04909502
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis treatment 2 suspended NCT00424788
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) treatment 0 completed NCT01201356
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis treatment 3 completed NCT02097849
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. treatment 2 completed NCT01873417
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States treatment 4 completed NCT06251986
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice No drug interventions Not Available Not Available recruiting NCT01903291
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS Not Available Not Available completed NCT02230969
Plegridy Observational Program Not Available Not Available completed NCT04676555
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis Not Available Not Available completed NCT04377555
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab. treatment 4 active_not_recruiting NCT04902690
The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients No drug interventions Not Available Not Available unknown_status NCT02834533
Role of Virtual Reality in MS Rehabilitation No drug interventions treatment Not Available completed NCT05359653
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy treatment 1 / 2 recruiting NCT06516458
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis No drug interventions Not Available Not Available recruiting NCT01252355
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta treatment 3 terminated NCT04237675
Postoperative Relapses in MS Patients No drug interventions Not Available Not Available recruiting NCT05218317
Evaluation of Relapse Presence in Multiple Sclerosis No drug interventions Not Available Not Available completed